Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
about
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling.Neuroblastoma: clinical and biological approach to risk stratification and treatment.Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.RAN/RANBP2 polymorphisms and neuroblastoma risk in Chinese children: a three-center case-control study.Treatment Outcomes in Children and Adolescents with Relapsed or Progressed Solid Tumors: a 20-year, Single-Center Study
P2860
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Revisions to the International ...... nical Trials Planning Meeting.
@en
type
label
Revisions to the International ...... nical Trials Planning Meeting.
@en
prefLabel
Revisions to the International ...... nical Trials Planning Meeting.
@en
P2093
P2860
P356
P1476
Revisions to the International ...... nical Trials Planning Meeting.
@en
P2093
Andrew D Pearson
Ariane Boubaker
Frank Berthold
Gudrun Schleiermacher
Jed G Nuchtern
John M Maris
Judith G Villablanca
Julie R Park
Katherine K Matthay
Kieran McHugh
P2860
P304
P356
10.1200/JCO.2016.72.0177
P407
P577
2017-05-04T00:00:00Z